Eyenuk, a company with worldwide operations in AI-powered medical technology and solutions and one of the leaders in AI-driven eye screening announced its penetration into the German market. Diabetes Center Mergentheim, the maiden hospital that has dedicated itself for leveraging AI in the diabetic retinopathy sphere in Germany was the first to adopt EyeArt. From October of 2018 when the technology was infused in the clinic’s operations, it has been able to precisely identify 10% of referable diabetic retinopathy (DR) cases, a major cause for vision loss in working adults.
This test can be done when a patient visits a medical facility for a regular diabetic check-up. The system, after capturing a patient’s eyes images, can process and deliver accurate results in less than 60 seconds. The results can be viewed and exported in a .pdf format as well. This breakthrough will help eye-surgeons invest time in resolving and researching vision-loss instead of spending the same amount of time in DR eye screening.
Before AI was adopted by Diabetes Center Mergentheim, the hospital saw 20,000 patients annually by diabetes specialists. For eyes, they were referred outside and patients complained that they never received an adequate, gratifying diagnosis. The hospital now screens 10-15 patients daily for this condition.
“EyeArt AI Eye Screening System is helping us improve diabetic patient care. We can now offer eye screening right in our clinic, without dilation, while reducing wait time for screening and results,” said Prof. Dr. med. Thomas Haak, head physician of Diabetes Center Mergentheim and a founding member and board director of DiabetesDE. “The accuracy and convenience of the EyeArt System are allowing us to identify and treat DR effectively and quickly. The patients with no referable DR feel good that they can be screened again in a year, and the patients with identified referable DR can feel good that their silently progressing retinopathy has been identified and will be treated before any loss of sight.”
“Last year, we began our partnership with Diabetes Center Mergentheim with a great promise, and now it is very gratifying to see the promise turning into the real meaningful impact that EyeArt System’s adoption is making to the diabetes patients in the Bad Mergentheim community,” said Kaushal Solanki, founder, and CEO of Eyenuk. “We are now replicating our success to clinics throughout Germany, taking us one more step further in realizing our mission to screen every eye in the world.”
Hence, technologies like EyeArt can be a boon for countries such as Germany because –
- 5 million people in Germany have diabetes
- Almost 2,500 patients lose their vision due to DR each year
- Although German regulations require patients-at-risk to be diagnosed annually, it is not practical due to a severe crunch of ophthalmologists in the country